Aa Aa Aa
  • Sucampo Pharma Americas, LLC

    4520 East West Highway, 3rd Floor

    Bethesda, MD 20814

    United States

    Phone: +01-301-961-3400

    Fax: +01-301-961-3440

    Email: info@sucampo.com

  • Sucampo Pharma Europe, Ltd. in the UK

    99 Park Drive, Milton Park

    Abingdon, Oxfordshire OX14 4RY

    United Kingdom

    Phone: +44-1235-841-544

    Fax: +44-1235-856-804

  • Sucampo AG in Switzerland

    Zug City Center

    Baarerstrasse 22

    6300 Zug


    Phone: +41-41-726-30-30

    Fax: +41-44-726-30-31

  • Sucampo Pharma, Ltd. in Japan

    Sakurabashi-Toyo Building, 4th Floor

    2-2-16 Sonezakishinchi, Kita-ku

    Osaka 530-0002


    Phone: +81-6-6343-9181

    Fax: +81-6-6343-0663

  • Sucampo Pharma, Ltd. in Japan

    Fukoku Seimei Building, 17th floor

    2-2-2 Uchisaiwai-cho Chiyoda-ku

    Tokyo 100-0011


    Phone: +81-3-5510-1041

    Fax: +81-6-6343-0663

Sucampo Pharmaceuticals, Inc. is a holding company that has the following direct and indirect wholly owned subsidiaries:

  • Sucampo Pharma Americas, LLC in the United States
  • Sucampo Pharma Europe, Ltd. in the United Kingdom
  • Sucampo Pharma, Ltd. in Japan
  • Sucampo AG in Switzerland

These companies provide services to Sucampo AG at its direction to develop and commercialize AMITIZA®, RESCULA® and other compounds covered by patents and patent applications held by Sucampo AG.

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs, to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and are also considering other potential therapeutic applications of our drug technologies.

Two products, AMITIZA and RESCULA, have received marketing approval globally. Our operations are conducted through subsidiaries based in the U.S., Japan, Switzerland, and the U.K.

Sucampo is a global biopharmaceutical company focused on the development and commercialization of medicines to meet the major unmet medical needs of patients on a global basis.

 In order to achieve this mission, we strive to:

  • Maximize net sales of AMITIZA® and develop and commercialize additional indications
  • Maximize net sales of RESCULA® and develop and commercialize additional indications
  • Seek new product opportunities while also pursuing strategic acquisitions and in-licensing opportunities that complement Sucampo’s portfolio

The 1980s marked an intense period of research and discovery for Sucampo founders Dr. Ryuji Ueno and Dr. Sachiko Kuno. Leading teams of talented scientists, Drs. Ueno and Kuno unlocked the therapeutic potential of prostones, which has resulted in two products available worldwide, several additional compounds currently in development and more than 660 patents and patent applications, including 350 active worldwide issued patents as of 2013.

Dr. Ueno and Dr. Kuno first founded what is now Sucampo in 1996 as R-Tech Ueno (USA), Inc. The success of this initial venture led them to found Sucampo Pharmaceuticals, Inc. and its wholly owned subsidiaries in the Americas, Asia and Europe. Our principal offices are located in Bethesda, Maryland.

Sucampo Pharmaceuticals, Inc. was founded by Sachiko Kuno, Ph.D. and Ryuji Ueno, M.D., Ph.D., Ph.D.

  • Sachiko Kuno, Ph.D.

    Founding CEO and Co-Founder

    Dr. Sachiko Kuno, Ph.D. is the founding CEO and Co-Founder of Sucampo Pharmaceuticals, Inc.  Dr. Kuno previously served as our chief executive officer from 1996 until November 2000 and from June 2004 until September 2006.  She also served as a member of our board of directors from 1996 until May 2007 and again from 2008 until September 2012.

    She has received a number of awards over the years, including an Ernst and Young Entrepreneur of the Year Award for the Greater Washington Area and the Washington Business Journal “Women Who Mean Business” award. Dr. Kuno holds a Ph.D. in industrial biochemistry from Kyoto University, and has conducted post-doctoral research at the Technical University of Munich, Germany, and certificate coursework in international business management at Georgetown University in Washington, DC.

  • Ryuji Ueno, M.D., Ph.D., Ph.D.


    Dr. Ryuji Ueno, Co-Founder of Sucampo Pharmaceuticals, Inc., is an internationally recognized expert in the pharmacology, physiology, and biochemistry of prostones — naturally occurring (endogenous) fatty acids–and their related compounds.

    During the 1980s, Dr. Ueno invented and developed therapeutic compounds based on his research with prostones. He was the first to identify the therapeutic potential of prostones as medicines, leading to the filing of more than 900 prostone-based patents worldwide.

    Dr. Ueno has published more than 100 articles in scientific journals, including The Lancet® and Proceedings of the National Academy of Sciences of the United States of America.  He obtained his M.D. and Ph.D. degrees in medicinal chemistry from Keio University (Japan), and earned a second Ph.D. in pharmacology from Osaka University (Japan).

  • Peter Greenleaf

    Chief Executive Officer

    Mr. Greenleaf became our chief executive officer and a director since March 2014. Prior to his leadership of Sucampo, Mr. Greenleaf was CEO and Board member of Histogenics, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. While at MedImmune, Mr. Greenleaf was instrumental in driving the expansion of MedImmune’s pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf also served as President of MedImmune Ventures from January 2010 to June 2013, a wholly owned venture capital fund within the AstraZeneca Group, where he led investment in emerging biopharmaceutical, medical device, and diagnostic companies. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and prior to that Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he also serves on the Governing Board of the Emerging Companies Section. Mr. Greenleaf’s previous Board appointments include the University of Maryland Baltimore Foundation, Inc.; Rib-X Pharmaceuticals; LigoCyte Pharmaceuticals; and Corridor Pharmaceuticals. He received a Master of Business Administration degree from St. Joseph’s University and a Bachelor of Science degree from Western Connecticut State University.

  • Stanley G. Miele

    Senior Vice President, Sales and Marketing President, Sucampo Pharma Americas, LLC.

    Since October 2008, Mr. Miele has been our senior vice president of sales and marketing. In September 2009, he was named as president of Sucampo Pharma Americas, LLC. Previously, he had been promoted from vice president of sales and national director of sales, positions he held when he first joined our company in February 2006. From October 2005 to January 2006, Mr. Miele was the i-STAT executive sales manager for Abbott Diagnostics, a division of Abbott Laboratories, a global healthcare company, and from January 2003 to September 2005 he held a series of positions at Millennium Pharmaceuticals, a pharmaceutical company, and COR Therapeutics, a pharmaceutical company, prior to its acquisition by Millennium, including national sales director, cardiology. Previously, Mr. Miele was a sales representative with the Hospital Products Division of Abbott Laboratories, and at Syntex Labs, a pharmaceutical company.

    Mr. Miele earned a B.A. in Management/Communications from the University of Dayton.

  • Thomas J. Knapp

    Executive Vice President, Chief Legal Officer & Corporate Secretary

    Mr. Knapp joined our company in February 2010 as senior vice president, general counsel and corporate secretary and was promoted to executive vice president, chief legal officer and corporate secretary in March 2012. Previously he was of counsel at Exemplar Law Partners, LLC, and a partner and member at Knapp Law Firm beginning September 2008. From March 2003 to August 2008, he was deputy general counsel and then vice president, general counsel and corporate secretary at NorthWestern Corporation, an electric and natural gas transmission and distribution company. From January 2001 to December 2002, Mr. Knapp served as of counsel at Paul Hastings LLP (f/k/a Paul, Hastings, Janofsky & Walker LLP), a leading international law firm, in Washington, D.C. and from May 1998 to December 2000 as assistant general counsel at The Boeing Company in Seattle, Washington. Mr. Knapp also served as of counsel at Paul Hastings LLP, in Washington, D.C. from May 1996 to April 1998 and he served in various in-house positions, including as labor counsel at The Burlington Northern & Santa Fe Railway Company in Chicago, Illinois and Fort Worth, Texas from September 1980 to December 1995.

    Mr. Knapp earned a B.A. in Political Science at the University of Illinois-Urbana and a J.D. at Loyola University of Chicago School of Law.